BD Launches High-Throughput Molecular Combination Test for COVID-19 and Influenza A/B
Second Test for the BD COR™ MX to be CE Marked to IVD DirectiveFRANKLIN LAKES, N.J., May 26, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new high-throughput molecular diagnostic combination test for SARS-CoV-2 and Influenza A...
Source: pharmiweb.com